Navigation Links
Late-breaking observational data show patients with type 2 diabetes taking JANUVIA® (sitagliptin) and metformin initiated insulin therapy at a slower rate compared to patients taking a sulfonylurea and metformin
Date:6/14/2014

WHITEHOUSE STATION, N.J., June 14, 2014 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a late-breaking observational study that assessed the differences in time to initiation of insulin use and the proportion of the population initiating insulin among patients with type 2 diabetes taking the combination of JANUVIA (sitagliptin) and metformin, and patients taking the combination of a sulfonylurea and metformin. In this study, patients treated with a combination of JANUVIA and metformin initiated insulin therapy at a slower rate during the period of observation than patients treated with a combination of sulfonylurea and metformin.

"Type 2 diabetes is a progressive disease, so that over time many patients need to add insulin to their treatment regimens to maintain blood sugar control," said Peter Stein, M.D., vice president, Clinical Research for diabetes and endocrinology, Merck Research Laboratories. "This study provides insight about different oral treatment regimens and their possible effect on initiation of insulin under real-world conditions. Real-world research is an important complement to clinical trials as we seek to improve patient health outcomes."

JANUVIA is indicated, as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus. JANUVIA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. JANUVIA has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk of developing pancreatitis while taking JANUVIA. JANUVIA is contraindicated in patients with a history of a serious hypersensitivity reaction to sitagliptin, such as anaphylaxis or angioedema.

Results from "Assessing time to insulin use among type 2 diabetes patients treated with sitagliptin or sulfonylurea plus metformin dual therapy"
'/>"/>

Contact: Pam Eisele
267-305-3558

Kim Hamilton
908-423-6831

Justin Holko
908-423-5088

Merck
Source:Eurekalert


Page: 1 2 3 4 5

Related medicine news :

1. Hot Line IV: Late-breaking trials on heart failure and acute coronary syndrome
2. A large, observational study of common gout treatment allopurinol shows less than half of patients reach recommended treatment goal
3. New post-hoc analysis shows patients with type 2 diabetes undergoing intensification of insulin therapy experienced less nighttime hypoglycemia while being treated with Januvia (Sitagliptin) compared to placebo
4. BRCA test results affect patients breast cancer surgery plans
5. Genotyping can predict disease outcomes in rheumatoid arthritis patients
6. Ipilimumab in advanced melanoma: added benefit for non-pretreated patients not proven
7. Recreational football can treat hypertensive and type 2 diabetes patients
8. Low cholesterol linked with worse survival in patients with kidney cancer
9. One-third of psoriatic arthritis patients are not receiving optimal dosing of adalimumab
10. Higher disease activity scores in obese RA patients
11. First clinical diabetes registry to provide seamless view of patients across specialties
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... With the Affordable Care Act (ACA) open enrollment period starting ... Research (AIR) finds that three out of four Americans are ... percent say they are not likely or only somewhat likely ... , The AIR survey found wide gaps in Americans’ health ... how much they owe for a routine doctor’s visit. , ...
(Date:10/22/2014)... Although there are only 24 hours in a day, that doesn’t ... finding time within their busy schedules for exercise and fitness. Fortunately, ... to get in shape. Here are five ways you can reach ... Change Up Your Commute , Consider riding a bike or taking ... your daily routine. If you must use your car to get ...
(Date:10/22/2014)... Salamon HealthDay Reporter , TUESDAY, ... vitro fertilization (IVF) are only about half as likely as ... technique, new research indicates, and the racial disparity persists even ... 31 percent of white patients became pregnant after IVF, compared ... than 4,000 IVF cycles over two years to tease out ...
(Date:10/22/2014)... HealthDay Reporter , MONDAY, Oct. 20, 2014 (HealthDay ... for health workers treating Ebola patients, now requiring full body ... at all times. The U.S. Centers for Disease Control ... Dallas nurses contracted Ebola while caring for the first ... Duncan. Nina Pham is currently being treated for her infection ...
(Date:10/20/2014)... The Advocator Group, LLC is proud ... for Suicide Prevention’s (AFSP) Out of the Darkness walk ... that hosts hundreds of community walks throughout the country ... to help understand and prevent suicide through not only ... , The Advocator Group shares this passion for ...
Breaking Medicine News(10 mins):Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 2Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 3
... tight spot, defending its position against the law suits ... drug, Zyprexa. The company is being blamed for ... being linked to obesity and high blood sugar. ... and internal communication between managers in the company, ample ...
... Madhya Pradesh took part in an AIDS awareness campaign and ... ,The students tied 'suraksha bandhan' (protection bands) on ... their commitment to spread this awareness. ,The students ... of Journalism here as part of a 'Unite for Children, ...
... and family gatherings to prepare for, the winter season ... expectations and the stresses of holiday events can increase ... of the most common illnesses for adults, seasonal blues ... or otherwise diagnosed,” said Waguih William IsHak, MD, medical ...
... lives of thousands of babies are being jeopardized by lack ... was spent on this subject during 2004-05, which accounts to ... a Department of Health spokeswoman said that spending on baby ... research into premature births can apply for a share of ...
... Scientists at the U.S. Department of Agriculture (USDA) have ... machine, used to measure// the body composition of infants. ... Body Composition System, the size of an infant was ... Ellis, at CNRC. The device was developed by Life ...
... Angeles has pressed upon Viagra manufacturers to put an end ... use as a recreational drug. ,Viagra which ... bisexual men who are also patronizing methamphetamine, giving a thrust ... Healthcare Foundation is especially worried that this could fuel the ...
Cached Medicine News:Health News:Mental Health Expert Offers Tips for a Happier Holiday Season 2Health News:Mental Health Expert Offers Tips for a Happier Holiday Season 3
(Date:10/22/2014)... N.J. , Oct. 22, 2014   ... a world-renowned leader in the field of infertility, ... approach to embryonic screening. The research abstract, released ... for Reproductive Medicine (ASRM) meeting in ... (CCS) and single gene defect (SGD) pre-implantation genetic ...
(Date:10/22/2014)... , Oct. 22, 2014  CryoLife, Inc. (NYSE: ... tissue processing company focused on cardiac and vascular surgery, ... President and Chief Executive Officer, has been elected to ... Steven G. Anderson , Executive Chairman ... has proven to be an excellent leader who is ...
(Date:10/22/2014)... CITY, Calif., Oct. 21, 2014 Abaxis, Inc. ... manufacturing point-of-care blood analysis systems, today reported financial results ... Second quarter overview: , Revenues of ... , Diluted EPS of $0.24, up 33% over ... , Service revenues from Abaxis Veterinary Reference Laboratories (AVRL) ...
Breaking Medicine Technology:New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3Pat Mackin Joins CryoLife Board of Directors 2Pat Mackin Joins CryoLife Board of Directors 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14
... , HARBIN, China, Nov. 17 /PRNewswire-Asia-FirstCall/ ... Company") (Nasdaq: CSKI ), a,leading fully integrated pharmaceutical company in ... the third quarter,of 2009. , , Third Quarter ... to $43.2 million, -- Gross profit increased 44.8% ...
... Mass., Nov. 17 Decision Resources, one of the world,s ... finds that, driven by the continued dominance of opioids that ... cancer pain drug market will increase from $2.3 billion in ... France, Germany, Italy, Spain, the United Kingdom and Japan. , ...
Cached Medicine Technology:China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 2China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 3China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 4China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 5China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 6China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 7China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 8China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 9China Sky One Medical, Inc. Announces Record Third Quarter 2009 Results 10The Cancer Pain Drug Market, Driven by the Continued Dominance of Opioids, Will Increase From $2.3 Billion in 2008 to $3.7 Billion in 2018 2
For the rapid determination of human chorionic gonadotropin (hCG) in urine. The test strip is used to obtain a visual qualitative result....
... GE Healthcares new Vivid i ... cardiovascular ultrasound system to provide high-performance, full-featured ... Vivid i addresses one ... access to complete, real-time diagnostic information. ...
... is an immunochromatographic in vitro assay for ... in human serum or plasma. Elevated concentration ... pathologies. It may also be caused by ... of IgE using InstaTest IgE test kit ...
... Through its unique and patented ... wires and trunk cables between patients ... monitors, allowing freedom of movement throughout ... technology, the LifeSync(R) System employs two-way ...
Medicine Products: